MARKET

VTGN

VTGN

Vistagen Therapeutics Inc
NASDAQ
2.970
-0.020
-0.67%
Closed 19:07 01/23 EST
OPEN
2.990
PREV CLOSE
2.990
HIGH
3.012
LOW
2.890
VOLUME
110.70K
TURNOVER
0
52 WEEK HIGH
5.74
52 WEEK LOW
2.220
MARKET CAP
82.70M
P/E (TTM)
-2.2813
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VTGN last week (0113-0117)?
Weekly Report · 4d ago
Vistagen announces results from PH284 study in cancer cachexia
TipRanks · 01/14 14:01
Vistagen Announces Results From Exploratory Phase 2A Study Of PH284 In Cancer Cachexia; PH284 Nasal Spray Demonstrated Improvements To Subjective Feelings Of Hunger In Cancer Patients
Benzinga · 01/14 13:32
VISTAGEN THERAPEUTICS INC - PHASE 2A STUDY EVALUATES EFFICACY, SAFETY, AND TOLERABILITY OF PH284
Reuters · 01/14 13:30
Weekly Report: what happened at VTGN last week (0106-0110)?
Weekly Report · 01/13 09:00
Vistagen enrolls first patient in repeat dose study of fasedienol
TipRanks · 01/10 14:01
Vistagen Announces Phase 3 Program For Social Anxiety Disorder With Fasedienol; First Enrollment In U.S. Study For Efficacy, Safety, Tolerability During Public Speaking Challenge
Benzinga · 01/10 13:37
VISTAGEN INITIATES FASEDIENOL REPEAT DOSE STUDY FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER
Reuters · 01/10 13:30
More
About VTGN
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.

Webull offers Vistagen Therapeutics Inc stock information, including NASDAQ: VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.